New York State Common Retirement Fund
KRYS icon

New York State Common Retirement Fund’s Krystal Biotech KRYS Stock Holding History

New York State Common Retirement Fund’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Buy
34,033
+2,691
+9% +$804K 0.02% 669
2026
Q1 		$8.1M Hold
31,342
– – 0.01% 814
2025
Q4 		$7.73M Buy
31,342
+4,348
+16% +$915K 0.01% 854
2025
Q3 		$4.77M Buy
26,994
+3,612
+15% +$541K 0.01% 1085
2025
Q2 		$3.21M Hold
23,382
– – ﹤0.01% 1238
2025
Q1 		$4.22M Hold
23,382
– – 0.01% 1116
2024
Q4 		$3.66M Sell
23,382
-2,481
-10% -$440K ﹤0.01% 1213
2024
Q3 		$4.71M Sell
25,863
-2,518
-9% -$486K 0.01% 1121
2024
Q2 		$5.21M Buy
28,381
+10,353
+57% +$1.74M 0.01% 1106
2024
Q1 		$3.21M Buy
18,028
+3,035
+20% +$422K ﹤0.01% 1288
2023
Q4 		$1.86M Sell
14,993
-7,091
-32% -$786K ﹤0.01% 1505
2023
Q3 		$2.56M Buy
22,084
+66
+0.3% +$8.05K ﹤0.01% 1358
2023
Q2 		$2.58M Sell
22,018
-2,423
-10% -$247K ﹤0.01% 1402
2023
Q1 		$1.96M Sell
24,441
-4,698
-16% -$369K ﹤0.01% 1546
2022
Q4 		$2.31M Sell
29,139
-8
-0% -$594 ﹤0.01% 1565
2022
Q3 		$2.03M Buy
29,147
+1,733
+6% +$125K ﹤0.01% 1596
2022
Q2 		$1.8M Buy
27,414
+348
+1% +$21.6K ﹤0.01% 1720
2022
Q1 		$1.8M Buy
27,066
+2,847
+12% +$178K ﹤0.01% 1799
2021
Q4 		$1.69M Sell
24,219
-1,940
-7% -$113K ﹤0.01% 1856
2021
Q3 		$1.37M Buy
26,159
+161
+0.6% +$9.53K ﹤0.01% 1972
2021
Q2 		$1.77M Buy
25,998
+3,425
+15% +$239K ﹤0.01% 1948
2021
Q1 		$1.74M Hold
22,573
– – ﹤0.01% 1858
2020
Q4 		$1.35M Buy
22,573
+2,362
+12% +$118K ﹤0.01% 1889
2020
Q3 		$870K Hold
20,211
– – ﹤0.01% 1979
2020
Q2 		$837K Buy
20,211
+2,400
+13% +$115K ﹤0.01% 1960
2020
Q1 		$770K Buy
17,811
+2,301
+15% +$120K ﹤0.01% 1841
2019
Q4 		$859K Buy
15,510
+500
+3% +$24.5K ﹤0.01% 2028
2019
Q3 		$521K Hold
15,010
– – ﹤0.01% 2306
2019
Q2 		$604K Buy
15,010
+8,432
+128% +$276K ﹤0.01% 2273
2019
Q1 		$216K Sell
6,578
-1,097
-14% -$25.9K ﹤0.01% 2687
2018
Q4 		$159K Buy
+7,675
New +$161K ﹤0.01% 2807

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

New York State Common Retirement Fund's KRYS Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Krystal Biotech (KRYS) stake by 8.6% in Q2 2026, buying an estimated $804K and bringing the position to 34,033 shares worth $12.6M. The position accounts for 0.02% of the portfolio, ranked #669.

New York State Common Retirement Fund first reported a position in KRYS in Q4 2018 and has held it in 31 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • New York State Common Retirement Fund held 34,033 shares of Krystal Biotech worth $12.6M as of Q2 2026.
  • New York State Common Retirement Fund bought 2,691 Krystal Biotech shares in Q2 2026, an estimated $804K.
  • Krystal Biotech made up 0.02% of New York State Common Retirement Fund's portfolio in Q2 2026, its #669 holding.
  • New York State Common Retirement Fund first reported a position in Krystal Biotech in Q4 2018 and has held it in 31 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.